Recent Antihyperglycemic Prescribing Trends for U.S. Privately Insured Patients With Type 2 Diabetes

Author:

Cohen Fredric J.1,Neslusan Cheryl A.2,Conklin Jonathan E.3,Song Xue3

Affiliation:

1. Johnson & Johnson Pharmaceutical Research and Development, Raritan, New Jersey

2. Johnson & Johnson Pharmaceutical Services, Raritan, New Jersey

3. The Medstat Group, Santa Barbara, California

Abstract

OBJECTIVE—The mid-1990s witnessed the introduction of new classes of medications to treat hyperglycemia of type 2 diabetes. There is evidence that these newer classes have found a place in the therapeutic armamentarium, but details of their use patterns are not known. We sought to determine whether antihyperglycemic prescribing patterns changed concurrently with new drug introductions, and whether such changes were related to changes in the underlying patient population. RESEARCH DESIGN AND METHODS—A sample of U.S. privately insured patients with suspected type 2 diabetes was identified from the MarketScan Research Database over the period of 1997–2000. Patients with type 2 diabetes were identified among those continuously enrolled in the database for at least 1 year. Drug therapy episodes were defined by sequential fulfillment of prescriptions implying a continuous supply of a particular drug (or combination) of at least 30 days duration. Univariate analyses were used to explore trends over time in drug prescriptions and patient characteristics. Multivariate logistic regressions were used to isolate the impact of year from other variables on the likelihood of receiving prescriptions for a specific therapy. RESULTS—A total of 232,020 unique diabetic patients had an average of 1.91 diabetes drug therapy episodes between 1997 and 2000. Monotherapy with sulfonylureas decreased, but monotherapy with thiazolidinedione, metformin, and other oral antihyperglycemics increased over time. Combinations of sulfonylureas and metformin; sulfonylureas and thiazolidinedione; metformin and thiazolidinedione; and sulfonylureas, metformin, and thiazolidinedione each increased over the time interval. Insulin monotherapy decreased, as did insulin combination therapy with sulfonylureas. The combination of insulin and metformin increased, whereas insulin and thiazolidinedione was stable. The influence of year on prescribing patterns remained highly significant (P < 0.001) after adjusting for patient characteristics. CONCLUSIONS—Antihyperglycemic prescription patterns in the U.S. have changed in recent years in parallel with, and probably as a direct result of, the introduction of different classes of medications to the marketplace. Overall, the prescribing trend has been away from monotherapy with insulins and sulfonylureas and toward combination therapies, presumably in attempts to reduce hypoglycemic symptoms and to achieve better glucose control.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference11 articles.

1. Defronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281–303, 1999

2. Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 287:360–372, 2002

3. Owens DR, Zinman B, Bolli GB: Insulins today and beyond. Lancet 358:739–746, 2001

4. Type 2 diabetes, study #35 [article online], 2002. Available from http://www.dresources.com/dr/Reports.nsf/BrowseAbstracts/2CC3CF7E3FEAEC5886256B7B0051F1B3?OpenDocument. Accessed 3 October 2002

5. The United States diabetes medication market [article online], 2001. Available from http://www.frost.com/prod/catlg.nsf/vwSegmentsByService?OpenView&svc=9634&fcmseq=1033073994029. Accessed 3 October 2002

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3